No financial data or catalysts were provided — this is a clinical data update only. Monitor for full POLARIS-1/2/3 data at future medical meetings and any FDA regulatory milestones (no PDUFA date set).
Price Chart
Executive Summary
Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation BCR-ABL1 inhibitor) and lisaftoclax (Bcl-2 inhibitor) across multiple hematologic malignancies. Olverembatinib showed statistically superior MMR rates vs standard TKI continuation in a controlled CML-CP trial (54.3% vs 10.0% at 6 months, P<0.001), and the POLARIS-1 Ph+ ALL study achieved 94.4% CR/CRi; lisaftoclax real-world AML data showed a 72% CR/CRi rate. Both assets remain investigational in the US with no FDA action date announced.
Key Facts
- Olverembatinib demonstrated a 54.3% 6-month MMR rate vs 10.0% in a controlled CML-CP trial (P<0.001)
- POLARIS-1 Ph+ ALL front-line study: 94.4% CR/CRi, 63.0% MRD-negative CR at end of induction
- Lisaftoclax real-world AML cohort: 72% CR/CRi, 61% MRD-negativity in responders
- Lisaftoclax Phase II CLL/SLL: median PFS 23.9 months, ORR 62.5% in BTKi-refractory patients
- Olverembatinib + lisaftoclax chemo-free combo in pediatric R/R Ph+ ALL yielded 88.9% ORR
- Both assets remain unapproved by US FDA — no approval or CRL event
Financial Impact
No financial results, guidance, or deal values were disclosed in this press release.
Risk Factors
- Both assets are not US FDA-approved — regulatory risk remains for POLARIS-1/2/3 trials
- No financial data or guidance was provided; stock may drift on lack of monetization catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311475 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.61 (+4.66%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.61 (+4.66%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.61 (+6.30%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.61 (−1.59%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.61 (+9.84%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.61 (−7.36%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.61 (−7.08%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.61 (−17.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.61 (−15.00%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.61 (−18.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers